- NOK416.64m
- NOK528.95m
- NOK512.00m
- 64
- 43
- 11
- 30
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 10.79 | ||
PEG Ratio (f) | 0.29 | ||
EPS Growth (f) | 60.04% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.71 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 132.86 | ||
Price to Sales | 0.77 | ||
EV to EBITDA | 8.44 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 13.69% | ||
Return on Equity | 10.82% | ||
Operating Margin | 8.74% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | NOKm | 188.75 | 209.88 | 278.44 | 382.13 | 512 | 536.7 | 626.5 | 22.72% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | +3396.73 | -40 | +86.02 | +57.77 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
Directors
- Terje Bakken CHM (53)
- Kathrine Gamborg Andreassen CEO
- Lars Hjarrand CFO
- Magnus Emmoth CEX (51)
- Per-Anders Elvertro CSO (42)
- Mattias von Haartman DSL
- Jostein Davidsen DRC
- Cheng Lu DRC
- Narve Reiten DRC (57)
- Inger Solberg DRC
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 4th, 2002
- Public Since
- March 31st, 2006
- No. of Shareholders
- 1,344
- No. of Employees
- 45
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 17,432,777
- Address
- Henrik Ibsens gate 100, OSLO, 0255
- Web
- https://navamedic.com/
- Phone
- +47 67112540
- Auditors
- Ernst & Young AS
Upcoming Events for NAVA
Similar to NAVA
Arctic Bioscience AS
Oslo Stock Exchange
Photocure ASA
Oslo Stock Exchange
Vistin Pharma ASA
Oslo Stock Exchange
FAQ
As of Today at 03:13 UTC, shares in Navamedic ASA are trading at NOK23.90. This share price information is delayed by 15 minutes.
Shares in Navamedic ASA last closed at NOK23.90 and the price had moved by -36.98% over the past 365 days. In terms of relative price strength the Navamedic ASA share price has underperformed the FTSE Global All Cap Index by -44.92% over the past year.
The overall consensus recommendation for Navamedic ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNavamedic ASA does not currently pay a dividend.
Navamedic ASA does not currently pay a dividend.
Navamedic ASA does not currently pay a dividend.
To buy shares in Navamedic ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK23.90, shares in Navamedic ASA had a market capitalisation of NOK416.64m.
Here are the trading details for Navamedic ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: NAVA
Based on an overall assessment of its quality, value and momentum Navamedic ASA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Navamedic ASA is NOK42.00. That is 75.73% above the last closing price of NOK23.90.
Analysts covering Navamedic ASA currently have a consensus Earnings Per Share (EPS) forecast of NOK1.48 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Navamedic ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24.85%.
As of the last closing price of NOK23.90, shares in Navamedic ASA were trading -27.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Navamedic ASA PE ratio based on its reported earnings over the past 12 months is 10.79. The shares last closed at NOK23.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Navamedic ASA's management team is headed by:
- Terje Bakken - CHM
- Kathrine Gamborg Andreassen - CEO
- Lars Hjarrand - CFO
- Magnus Emmoth - CEX
- Per-Anders Elvertro - CSO
- Mattias von Haartman - DSL
- Jostein Davidsen - DRC
- Cheng Lu - DRC
- Narve Reiten - DRC
- Inger Solberg - DRC